Как улучшить контроль над бронхиальной астмой без увеличения объема базисной терапии?
https://doi.org/10.18093/0869-0189-2013-0-1-77-84
Аннотация
Как улучшить контроль над бронхиальной астмой без увеличения объема базисной терапии?
Об авторах
А. И. Синопальников
Российская медицинская академия последипломного образования
Россия
Россия
д. м. н., проф., зав. кафедрой пульмонологии
123995, Москва, ул. Баррикадная, 2 / 1
Ю. Г. Белоцерковская
Российская медицинская академия последипломного образования
Россия
Россия
к. м. н., доцент кафедры пульмонологии
123995, Москва, ул. Баррикадная, 2 / 1
Список литературы
1. Global Strategy for Asthma Management and Prevention (GINA). Updated 2011. Available on www.ginasthma.org
2. Global Initiative for Obstructive Lung Disease (GOLD). Revised 2011. Availlable on www.goldcopd.org
3. Giraud V., Allaert F.A., Roche N. Inhaler technique and asthma: feasability and acceptability of training by pharmacists. Respir. Med. 2011; 105 (12): 1815–1822.
4. Brocklebank D., Ram F., Wright J. et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airway disease; a systematic review of the literature. Hlth Technol. Assess 2001; 5: 1–149.
5. Dolovich M.B., Ahrens R.C., Hess D.R. et al. Device selection and outcomes of aerosol therapy: evidence–based guidelines: American College of Chest Physicians / American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335–371.
6. Molimard M., Raherison C., Lignot M. et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol. Med. 2003; 16: 249–254.
7. Lavorini F., Magnan A., Dubus J.C. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 2008; 102: 593–604.
8. Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and associated with reduced disease control. Respir. Med. 2011; 105: 930–938.
9. Kobrich R., Rudolf G., Stahlhofen W. A mathematical model of mass deposition in man. Ann. Occup. Hyg. 1994; 38: 15–23.
10. Pauwels R., Newman S., Borgstrom L. Airway deposition and the airway effects of antiasthma drugs delivered from metered–dose inhalers. Eur. Respir. J. 1997; 10: 2127–2138.
11. Laube B.L., Janssens H.M., de Jongh F.H.C. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37: 1308–1331.
12. Hendeles L., Colice G.L., Meyer R.J.Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants. N. Engl. J. Med. 2007; 356: 1344–1351.
13. Thorsson L., Edsbacker S. Lung deposition of budesonide from a pressurized metered–dose inhaler attached to a spacer. Eur. Respir. J. 1998; 12: 1340–1345.
14. Ganderton D. Targeted delivery of inhaled drugs: current challenges and future goal. J. Aerosol. Med. 1999; 12 (Suppl. 1): S3–S8.
15. Scichilone N., Spatofora M., Battaglia S. et al. Lung penetration and patient adherence considerations in the management of asthma: role of extra–fine formulations. J. Asthma and Allergy 2013; 6: 11–21.
16. Leach C.L., Kuehl P.J., Chand R. et al. Characterization of respiratory deposition of fluticasone–salmeterol hydrofluoroalkane–134a and hydrofluoroalkane–134a beclomethasone in asthmatic patients. Ann. Allergy Asthma Immunol. 2012; 108 (3): 195–200.
17. Mariotti F., Poli G., Acerbi D. et al. 2007 Lung deposition of BDP / formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients [abstract]. Poster presented at the VIII UIP National congress, Florence, 4–7 December 2007.
18. Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J. Allergy Clin. Immunol. 2007; 120: 1269–1275.
19. Scichilone N., Battaglia S., Olivieri D., Bellia V. The role of small airways in monitoring the response to asthma treatment: what is beyond FEV1? Allergy 2009; 64: 1563–1569.
20. Frey U., Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet 2008; 372: 1088–1099.
21. Beigelman–Aubry C., Capderou A., Grenier P.A. et al. Mild intermittent asthma: CT assessment of bronchial cross–sectional area and lung attenuation at controlled lung volume. Radiology 2002; 223: 181–187.
22. Ueda T., Niimi A., Matsumoto H. et al. Role of small airways in asthma: investigation using high–resolution computed tomography. J. Allergy Clin. Immunol. 2006; 118: 1019–1025.
23. Bourdin A., Paganin F., Prefaut C. et al. Nitrogen washout slope in poorly controlled asthma. Allergy 2006; 61: 85–89.
24. Battaglia S., den Hertog H., Timmers M.C. et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005; 60: 639–644.
25. Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur. Respir. J. 2002; 20: 841–845.
26. Berry M., Hargadon B., Morgan A. et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur. Respir. J. 2005; 25: 986–991.
27. Yixin S., Aledia A.S., Tatavoosian A.V. et al. Relating small airways to asthma control by using impulse oscillometry in children. J. Allergy Clin. Immunol. 2012; 129: 671–678.
28. Yanai M., Sekizawa K., Ohrui T. et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J. Appl. Physiol. 1992; 72: 1016–1023.
29. Contoli M., Kraft M., Hamid Q. et al. Do small airway abnormalities characterize asthma phenotypes? In search of proof. Clin. Exp. Allergy 2012; 42: 1150–1160.
30. Global Strategy for Asthma Management and Prevention (GINA). Updated 2011. Available on www.ginasthma.org
31. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guide–line–defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med. 2004; 170 (8): 836–844
32. Greening A.P., Ind P.W., Northfield M. et al. Added salmeterol versus higher–dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–224.
33. Pauwels R.A., Lofdahl C.G., Postma D.S. et al. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405–1411.
34. Papi A., Paggiaro P., Nicolini G. et al. Beclomethasone / for moterol vs fluticasone / salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62 (10): 1182–1188.
35. Huchon G., Magnussen H., Chuchalin A. et al. Lung function and asthma control with beclometha– sone and formoterol in a single inhaler. Respir. Med. 2009; 103 (1): 41–49.
36. Scichilone N., Battaglia S., Sorino C. et al. Effects of extra–fine inhaled beclomethasone / formoterol on both large and small airways in asthma. Allergy 2010; 65 (7): 897–902.
37. Muller V., Galffy G., Eszes N. et al. Asthma control in patients receiving inhaled corticosteroid and long–acting beta2–agonist fixed combinations. A real–life study comparing dry powder inhalers and a pressurized metered dose inhaler extra–fine formulation. BMC Pulm. Med. 2011; 11: 40.
38. Allegra L., Cremonesi G., Girbino G. et al. Real–life prospective study on asthma control in Italy: cross–sectional phase results. Respir. Med. 2012; 106 (2): 205–214.
39. Papi A., Paggiaro P.L., Nicolini G. et al. Beclomethasone /formoterol versus budesonide / formoterol combination therapy in asthma. Eur. Respir. J. 2007; 29 (4): 682–689.
40. Papi A., Nicolini G., Crimi N. et al. Step–down from high dose fixed combination therapy in asthma patients: a randomized controlled trial. Respir. Res. 2012; 13: 54.
41. Goldin J.G., Tashkin D.P., Kleerup E.C. et al. Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipro– pionate inhalation on small airways: assessment with functional helical thin–section computed tomography. J. Allergy Clin. Immunol. 1999; 104 (6): S258–S267.
42. Terzano С., Cremonesi G., Girbino G. et al. 1–year prospective real life monitoring of asthma control and quality of life in Italy. Respir. Res. 2012, 13: 112–123.
Рецензия
Для цитирования:
Синопальников А.И., Белоцерковская Ю.Г. Как улучшить контроль над бронхиальной астмой без увеличения объема базисной терапии? Пульмонология. 2013;(1):77-84. https://doi.org/10.18093/0869-0189-2013-0-1-77-84
For citation:
Sinopalnikov A.I., Belotserkovskaya Yu.G. How can we improve asthma control without escalating therapy? PULMONOLOGIYA. 2013;(1):77-84. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-1-77-84
Просмотров:
713
Послать статью по эл. почте 